Identification of Biomarkers for Prediction of Hepatocellular Carcinoma after Elimination of Hepatitis C Virus by Antiviral Medicines, mavilet
Not Applicable
Recruiting
- Conditions
- Chronic hepaititis due to HCV Compensated liver cirroshis due to HCV
- Registration Number
- JPRN-UMIN000031098
- Lead Sponsor
- Kanazawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with a history of hypersensitivity to any of the ingredients of Maviret (CONTRAINDICATIONS in the package insert) 2)Patients who are using any of contraindicated co-medications listed in the package insert 3)Patients with severe liver dysfunction (Child-Pugh classification C) (CONTRAINDICATIONS in the package insert) 4)Patients who have received treatment for hepatcellular carcinoma within the past 12 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of New Biomarkers for Prediction of Hepatocellular Carcinoma after Eliminating Hepatitis C Virus
- Secondary Outcome Measures
Name Time Method 1)Identification of new biomarkers for prediction of hepatocellular carcinoma after eliminating Hepatitis C Virus 2)Analysis on HCV amino acid/nucleotide sequences (core, NS5A, and NS5B) 3)Analysis on cytokines in peripheral blood 4)Analysis of gene profiling of liver obatained by liver biopsy 5)Analysis of Fibroscan 6)Analysis glucose/lipid metabolism 7)Analysis of gene profiling of peripheral blood lymphocyte 8)Quantification of laminin gamma 2 monomer in serum